Excedrin and Tylenol Suffer Recall Headache

Can Novartis and J&J win back consumer confidence in their pain-reliever brands?

Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

It’s enough to give brand marketers a whopping headache.

After years of brand advertising around famous slogans such as “Excedrin Headache Number 24,” Excedrin products were voluntarily and quietly yanked from shelves last January due to manufacturing problems, including pills of other products accidentally showing up in Excedrin bottles.

Parent company Novartis initially promised that part of the Excedrin product line would reappear this summer, but now the date has been pushed to the fourth quarter of 2012, according to a Novartis OTC rep.

In the meantime, several of Johnson & Johnson’s Tylenol products are still hard to find after three years of voluntary recalls.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in